Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Inclusion Criteria: * Age ≥ 18 and ≤ 80 years * The diagnosis of ICH is confirmed by brain CT scan * NIHSS score ≥6 and GCS \>6 upon presentation * The first dose of the study drug is expected to be administered within 24h of ICH symptom onset * Functional independence prior to ICH, defined as pre-ICH mRS ≤1 * Signed and dated informed consent is obtained. Exclusion Criteria: * Previous chelation therapy or known hypersensitivity to DFO products * Known severe iron deficiency anemia (defined as hemoglobin concentration \< 7g/dL or requiring blood transfusions) * Abnormal renal function, defined as serum creatinine \>2 mg/dL * Planned surgical evacuation of ICH prior to administration of study drug (placement of a catheter for ventricular drainage is not a contraindication to enrollment) * SUSPECTED secondary ICH related to tumour, ruptured aneurysm or arteriovenous malformation, hemorrhagic transformation of an ischemic infarct, or venous sinus thrombosis * Infratentorial hemorrhage * Irreversibly impaired brainstem function (bilateral fixed and dilated pupils and extensor motor posturing) * Complete unconsciousness, defined as a score of 3 on item 1a of the NIHSS (Responds only with reflex motor or autonomic effects or totally unresponsive, and flaccid) * Pre-existing disability, defined as pre-ICH mRS ≥2 * Coagulopathy - defined as elevated aPTT or INR \>1.3 upon presentation; concurrent use of direct thrombin inhibitors (such as dabigatran), direct factor Xa inhibitors (such as rivaroxaban or apixaban), or low-molecular-weight heparin * Patients with confirmed aspiration, pneumonia, or evident bilateral pulmonary infiltrates on chest x-ray or CT scan prior to enrollment * Patients with significant respiratory disease such as chronic obstructive pulmonary disease, pulmonary fibrosis, or any use (chronic or intermittent) of inhaled O2 at home * FiO2 \>0.35 (\>4 L/min) prior to enrollment * Sepsis (present source of infection ± lactic acidosis); Systemic Inflammatory Response Syndrome (Temp \>100.4F or \<96.8F; Heart rate \>90; Respiratory rate \>20 or PaCo2 \<32 mmHg; WBC \>12, \<4, or bands \>10%); or shock (SBP \<90 mmHg) at presentation * The presence of 4 or more of the following risk modifiers for ARDS prior to enrollment: 1. Tachypnea (respiratory rate \>30) 2. SpO2 \<95% 3. Obesity (BMI \>30) 4. Acidosis (pH \<7.35) 5. Hypoalbuminemia (albumin \<3.5 g/dL) 6. Concurrent use of chemotherapy * Taking iron supplements containing ≥ 325 mg of ferrous iron, or prochlorperazine * Patients with heart failure taking \> 500 mg of vitamin C daily * Known severe hearing loss * Known pregnancy, or positive pregnancy test, or breastfeeding * Positive drug screen for cocaine upon presentation * Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, noncompliance, living in another state or any other cause * Any condition which, in the judgement of the investigator, might increase the risk to the patient * Life expectancy of less than 90 days due to co-morbid conditions * Concurrent participation in another research protocol for investigation of another experimental therapy * Indication that a new DNR or Comfort Measures Only (CMO) order will be implemented within the first 72 hours of hospitalization